Skip to main content

Advertisement

SpringerLink
Log in

Use of statins in patients with liver disease

  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

Cardiovascular disease is as common in individuals with chronic liver disease as in the general population. Moreover, recent data suggest that patients with nonalcoholic fatty liver disease (NAFLD) may have a cardiovascular risk greater than that conferred by the conventional risk factors. There is unequivocal evidence that cardiovascular disease is an important cause of morbidity and mortality in this patient population and thus requires consideration of aggressive therapy with lipid-lowering agents such as statins. Because all statins are hepatically cleared and can cause elevations in liver biochemistries, there is a concern that patients with underlying liver disease may be at increased risk for hepatotoxicity. However, recent data, along with an assessment of statin safety by the Liver Expert Panel, suggest that statins are generally well tolerated in patients with chronic liver disease such as NAFLD, primary biliary cirrhosis, and hepatitis C virus. These drugs also appear to be safe in patients with stable/compensated cirrhosis. However, decompensated cirrhosis and acute liver failure should be considered contraindications for lipid-lowering therapy as these patients are unlikely to benefit because of their generally grave prognosis. Although routine hepatic biochemical test monitoring is recommended, the cost-effectiveness of this approach has been questioned. The benefit of statins in patients with underlying liver disease who are otherwise important candidates for statin therapy far outweighs the risk of a very rare event of serious liver injury.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Clark JM, Brancati FL, Diehl AM: The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003, 98:960–967.

    Article  PubMed  CAS  Google Scholar 

  2. Rafiq N, Bai C, Fang Y, et al.: Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009, 7:234–238.

    Article  PubMed  Google Scholar 

  3. Targher G, Marra F, Marchesini G: Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 2008, 51:1947–1953.

    Article  PubMed  CAS  Google Scholar 

  4. Targher G, Bertolini L, Padovani R, et al.: Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol 2007, 46:1126–1132.

    Article  PubMed  CAS  Google Scholar 

  5. Shalev V, Chodick G, Silber H, et al.: Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch Intern Med 2009, 169:260–268.

    Article  PubMed  Google Scholar 

  6. Brown WV: Safety of statins. Curr Opin Lipidol 2008, 19:558–562.

    Article  PubMed  CAS  Google Scholar 

  7. de Denus S, Spinler SA, Miller K, Peterson AM: Statins and liver toxicity: a meta-analysis. Pharmacotherapy 2004, 24:584–591.

    Article  PubMed  Google Scholar 

  8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2497.

    Article  Google Scholar 

  9. Tolman KG: The liver and lovastatin. Am J Cardiol 2002, 89:1374–1380.

    Article  PubMed  CAS  Google Scholar 

  10. Chalasani N, Fontana RJ, Bonkovsky HL, et al.: Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008, 135:1924–1934.

    Article  PubMed  Google Scholar 

  11. Browning JD, Szczepaniak LS, Dobbins R, et al.: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387–1395.

    Article  PubMed  Google Scholar 

  12. Chalasani N, Aljadhey H, Kesterson J, et al.: Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004, 126:1287–1292.

    Article  PubMed  CAS  Google Scholar 

  13. Vuppalanchi R, Teal E, Chalasani N: Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005, 329:62–65.

    Article  PubMed  Google Scholar 

  14. Pfeffer MA, Keech A, Sacks FM, et al.: Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation 2002, 105:2341–2346.

    Article  PubMed  CAS  Google Scholar 

  15. Hyogo H, Tazuma S, Arihiro K, et al.: Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008, 57:1711–1718.

    Article  PubMed  CAS  Google Scholar 

  16. Ahmed MH: Rosuvastatin: a safe and effective treatment for dyslipidaemia associated with non-alcoholic steatohepatitis (NASH). Scand J Gastroenterol 2006, 41:631.

    Article  PubMed  CAS  Google Scholar 

  17. Rallidis LS, Drakoulis CK, Parasi AS: Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis 2004, 174:193–196.

    Article  PubMed  CAS  Google Scholar 

  18. Sheikh MY, Choi J, Qadri I, et al.: Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology 2008, 47:2127–2133.

    Article  PubMed  CAS  Google Scholar 

  19. Hanouneh IA, Feldstein AE, Lopez R, et al.: Clinical significance of metabolic syndrome in the setting of chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2008, 6:584–589.

    Article  PubMed  Google Scholar 

  20. Khorashadi S, Hasson NK, Cheung RC: Incidence of statin hepatotoxicity in patients with hepatitis C. Clin Gastroenterol Hepatol 2006, 4:902–907.

    Article  PubMed  CAS  Google Scholar 

  21. Gibson K, Rindone JP: Experience with statin use in patients with chronic hepatitis C infection. Am J Cardiol 2005, 96:1278–1279.

    Article  PubMed  CAS  Google Scholar 

  22. Segarra-Newnham M, Parra D, Martin-Cooper EM: Effectiveness and hepatotoxicity of statins in men seropositive for hepatitis C virus. Pharmacotherapy 2007, 27:845–851.

    Article  PubMed  CAS  Google Scholar 

  23. Sorokin A, Brown JL, Thompson PD: Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. Atherosclerosis 2007, 194:293–299.

    Article  PubMed  CAS  Google Scholar 

  24. Longo M, Crosignani A, Battezzati PM, et al.: Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut 2002, 51:265–269.

    Article  PubMed  CAS  Google Scholar 

  25. Solaymani-Dodaran M, Aithal GP, Card T, West J: Risk of cardiovascular and cerebrovascular events in primary biliary cirrhosis: a population-based cohort study. Am J Gastroenterol 2008, 103:2784–2788.

    Article  PubMed  Google Scholar 

  26. Allocca M, Crosignani A, Gritti A, et al.: Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. Gut 2006, 55:1795–1800.

    Article  PubMed  CAS  Google Scholar 

  27. Stojakovic T, Putz-Bankuti C, Fauler G, et al.: Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology 2007, 46:776–784.

    Article  PubMed  CAS  Google Scholar 

  28. Ritzel U, Leonhardt U, Nather M, et al.: Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. J Hepatol 2002, 36:454–458.

    Article  PubMed  CAS  Google Scholar 

  29. Abu Rajah MA, Kaplan MM: Statin use in patients with primary biliary cirrhosis (PBC): are they safe [abstract]? Gastroenterology 2007, 132:A732.

    Google Scholar 

  30. Lipitor [package insert]. New York, NY: Pfizer, Inc.; 2004.

  31. Crestor [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals; 2003.

  32. Mevacor [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2002.

  33. Zocor [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2004.

  34. Lewis JH, Mortensen ME, Zweig S, et al.: Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007, 46:1453–1463.

    Article  PubMed  CAS  Google Scholar 

  35. Cohen DE, Anania FA, Chalasani N: An assessment of statin safety by hepatologists. Am J Cardiol 2006, 97:77C–81C.

    Article  PubMed  CAS  Google Scholar 

  36. Abraldes J, Albillos A, Bañares R, et al.: Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 2009, 136:1651–1658.

    Article  PubMed  CAS  Google Scholar 

  37. Kawata S, Yamasaki E, Nagase T, et al.: Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001, 84:886–891.

    Article  PubMed  CAS  Google Scholar 

  38. Lersch C, Schmelz R, Erdmann J, et al.: Treatment of HCC with pravastatin, octreotide, or gemcitabine—a critical evaluation. Hepatogastroenterology 2004, 51:1099–1103.

    PubMed  CAS  Google Scholar 

  39. Muñoz SJ: Hyperlipidemia and other coronary risk factors after orthotopic liver transplantation: pathogenesis, diagnosis, and management. Liver Transpl Surg 1995, 1(Suppl 1):29–38.

    PubMed  Google Scholar 

  40. Fernandez-Miranda C, Sanz M, dela Calle A, et al.: Cardiovascular risk factors in 116 patients 5 years or more after liver transplantation. Transpl Int 2002, 15:556–562.

    Article  PubMed  Google Scholar 

  41. Martin JE, Cavanaugh TM, Trumbull L, et al.: Incidence of adverse events with HMG-CoA reductase inhibitors in liver transplant patients. Clin Transplant 2008, 22:113–119.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Indiana University School of Medicine, 1050 Wishard Boulevard, RG 4100, Indianapolis, IN, 46202, USA

    Raj Vuppalanchi

Authors
  1. Sweta Tandra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raj Vuppalanchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Raj Vuppalanchi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tandra, S., Vuppalanchi, R. Use of statins in patients with liver disease. Curr Treat Options Cardio Med 11, 272–278 (2009). https://doi.org/10.1007/s11936-009-0028-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-009-0028-2

Keywords

Search

Navigation